Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genexol-PM plus cisplatin versus paclitaxel injection plus cisplatin for first-line advanced NSCLC
ChiCTR-IPR-15006252Phase 3Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Mar 2015
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Genexol-PM + cisplatin with Paclitaxel injection + cisplatin (2 arms). Primary endpoint: objective response rate. Started Mar 2015; status: recruiting.
02
Drugs
paclitaxel polymeric micellepaclitaxelcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IPR-15006252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006252.